Abstracts tagged "autoimmune diseases"

Abstract Number: 0351 • ACR Convergence 2022
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Yasuhiro Hasegawa¹, Yoshiyuki Arinuma², Yu Matsueda¹, Kenji Oku³ and Kunihiro Yamaoka⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University, Kanagawa, Japan, ³Kitasato University, Chigasaki, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…
Abstract Number: 0622 • ACR Convergence 2022
Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients
Sumbul Afroz¹, Lea Williams¹, Ruozhang Xu¹, Joshua F. Baker², Anupama Shahane² and Laura F. Su³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Perelman School of Medicine, Philadelphia, PA, ³Department of Medicine, Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Past studies have shown a critical link between alteration in human commensal microbiota and development of Rheumatoid Arthritis (RA), however how CD4+ T-cell responses…
Abstract Number: 0716 • ACR Convergence 2022
Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic
Jack Ellrodt¹, Emily G Oakes¹, Laura Kubzansky², Karestan Koenen², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: Posttraumatic Stress Disorder (PTSD), a complex psychiatric disorder that can result from experiencing or witnessing a traumatic event, such as an accident, assault, or…
Abstract Number: 0770 • ACR Convergence 2022
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
Amarah Baluch¹, Katerina Warda², Taylor Middleton², Kiersten Kennedy², Andras Perl³ and Jihad Ben Gabr¹, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical Unviersity, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Immune check point inhibitors (ICIs) boost the patient's immune system by blocking intrinsic down-regulators of immunity by signaling through cytotoxic T-lymphocyte antigen 4 (CTLA-4),…
Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Stephanie Wong¹, Lori Tucker², Kristin Houghton³, David Cabral⁴, Mercedes Chan², Ross Petty³, Andrea Human², Kimberly Morishita³, Rae Yeung⁵, Kiem Oen⁶, Ciaran Duffy⁷, Roberta Berard⁸, Gaelle Chedeville⁹, Thomas Loughin¹⁰, Matthew Berkowitz¹⁰ and Jaime Guzman¹¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁴BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶University of Manitoba, Toronto, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸London Health Sciences Centre, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Simon Fraser University, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…
Abstract Number: 1138 • ACR Convergence 2022
Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection and Common Molecular Signatures with Autoimmune Diseases
Guillermo Barturen¹, Elena Carnero-Montoro¹, Manuel Martinez-Bueno¹, Silvia Rojo-Rello², Beatriz Sobrino³, Clara Alcántara-Domínguez⁴, David Bernardo⁵ and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²Hospital Clínico Universitario, Valladolid, Spain, ³Hospital Regional de Málaga, Málaga, Spain, ⁴Lorgen G.P., SL, Granada, Spain, ⁵Universidad de Valladolid-CSIC, Valladolid, Spain
Background/Purpose: SARS-CoV-2 causes a severe inflammatory syndrome (COVID-19) leading, in many cases, to bilateral pneumonia, severe dyspnea and in ~5% of these, death. DNA methylation…
Abstract Number: 1341 • ACR Convergence 2022
Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
Silera Holguin Balbuena, Anna Radisic, Sarah Goodman, Shreya Gor, Beatrice Wood, Alexander Shahin, Kelara Samuel, Rahul Mhaskar and John Carter, University of South Florida, Tampa, FL
Background/Purpose: The spread of COVID-19 began in December 2019 and quickly escalated into a global pandemic resulting in millions of deaths. Many factors are associated…
Abstract Number: 1628 • ACR Convergence 2022
The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome
Raphaèle Seror¹, Gabriel Baron², Divi CORNEC³, Elodie Perrodeau², Marine Camus⁴, Professor Simon Bowman⁵, Michele Bombardieri⁶, Hendrika Bootsma⁷, Suzanne Arends⁷, jacques-eric gottenberg⁸, Benjamin A. Fisher⁹, Wolfgang Hueber¹⁰, Joel Van Roon¹¹, Valerie Devauchelle¹², Liseth de Wolff¹³, Peter Gergely¹⁴, Xavier Mariette¹⁵ and Raphaël Porcher¹⁶, ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³CHRU Brest, Brest, France, ⁴Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, ⁵University Hospitals Birmingham, Birmingham, United Kingdom, ⁶Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸Strasbourg University Hospital, Strasbourg, France, ⁹University of Birmingham, Birmingham, United Kingdom, ¹⁰Novartis Pharmaceuticals, Basel, Switzerland, ¹¹Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, ¹²Université de Bretagne Occidentale, Brest, France, ¹³UMCG, Zwolle, Netherlands, ¹⁴Novartis Pharma, Basel, Switzerland, ¹⁵Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁶Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
Abstract Number: 1780 • ACR Convergence 2022
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
Paola Ghanem¹, Joseph C. Murray¹, Christopher Mecoli², Ami Shah³, Benjamin Levy¹, Kristen A. Marrone¹, David Ettinger¹, Valsamo Anagnostou¹, Vincent K. Lam¹, Julie R. Brahmer¹ and Laura C. Cappelli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Lung cancer remains the leading cause of cancer-related death. Concomitant autoimmune diseases (AD) can add morbidity and complicate treatment decisions. We evaluated the tumor…
Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
Abstract Number: PP21 • ACR Convergence 2022
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY
Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
Abstract Number: 0008 • ACR Convergence 2022
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Jennifer Barnas¹, Diana Alzamareh², Nida Meednu² and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…
Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Ronald Van Vollenhoven¹, Eric F. Morand², Richard A. Furie³, Ian N. Bruce⁴, Gabriel Abreu⁵, Raj Tummala⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, ²Monash University, Melbourne, Australia, ³Northwell Health, Great Neck, NY, ⁴The University of Manchester, Manchester, United Kingdom, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Gaithersburg, MD, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸AstraZeneca, Gothenburg, Sweden
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
Abstract Number: 0635 • ACR Convergence 2022
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Lucy Marie Carter¹, Md Yuzaiful Md Yusof², Darren Plant³, Julien Bauer⁴, Stephanie Wenlock⁴, Adewonuola Alase¹, Antonios Psarras¹, Zoe Wigston¹ and Edward M Vital², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Anti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). ANA may become positive years in advance of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].